Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Summary

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

Timeline

Start

2024-12-16

Primary completion

2027-05-30

Completion

2027-08-30

Drugs

Indications